New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
12:25 EDTWWWW, MEET, VRTX, WAG, GOOG, EIGI, MUOn The Fly: Midday Wrap
Stocks on Wall Street were higher at midday after reports on new home sales and consumer confidence both rose to their best levels in six years. The major averages began the day slightly below the flat-line but crossed into positive ground following the confidence and new home sales reports at 10 am ET, after which they found a level and have barely moved since. ECONOMIC EVENTS: In the U.S., the S&P/Case-Shiller index of property values in 20 cities for April had its smallest 12-month gain in more than a year, rising 10.8% from the same month of last year. However, a separate report showed that new home sales surged 18.6% in May to a 504K annual rate, beating expectations. The Conference Board's consumer confidence index climbed to 85.2 in June, beating expectations and hitting its highest level since 2008. The Richmond Fed manufacturing index dipped to 3 in June from 7 in both April and May. COMPANY NEWS: Shares of computer memory maker Micron Technology (MU) climbed 5% after the company's third quarter earnings per share and revenue surpassed analysts' expectations. Following its report and guidance last night, Needham upgraded Micron to Strong Buy from Buy and raised its price target for shares to $50 from $40, while analysts at Roth Capital, Jefferies, and JPMorgan also raised their price targets on the stock. Conversely, Walgreen (WAG) slipped 1% after its earnings missed expectations and it withdrew the FY16 goals the company had previously announced in 2012. Walgreen cited the consideration its board is making of the second step in its Alliance Boots strategic transaction as the reason for withdrawing the targets and said its expects to provide a new set of goals and metrics by late July or early August. MAJOR MOVERS: Among the notable gainers was Vertex Pharmaceuticals (VRTX), which was up about 40% after Phase 3 studies of its combination treatment for lung function in certain cystic fibrosis patients achieved their primary endpoint. Also higher was MeetMe (MEET), which rose 18% after the company announced that it set a new daily record for the number of user-to-user chats as more than 15 million chats were sent on a single day for the first time on its service. Among the noteworthy losers was Web.com (WWWW), which dropped 21% after Google (GOOG) entered the domain name market and announced that it would enable individuals and businesses to choose Internet addresses. Also lower following Google's entry into the domain name market was another company in the sector, Endurance (EIGI), which dropped more than 10%. INDEXES: Near midday, the Dow was up 12.00, or 0.07%, to 16,949.26, the Nasdaq was up 28.52, or 0.65%, to 4,397.19, and the S&P 500 was up 3.54, or 0.18%, to 1,966.15.
News For WWWW;GOOG;VRTX;MU;WAG;MEET;EIGI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
January 13, 2015
07:15 EDTMUNeedham to hold a conference
Subscribe for More Information
January 12, 2015
16:32 EDTMUOn The Fly: Closing Wrap
Stocks spent almost the entire session in negative territory as the continued slump in crude oil prices weighed on equities. As the price of crude searches for a bottom, analysts and investors are concerned about how the low prices may affect U.S. economic growth. It had been estimated that more than half of the expected growth in the S&P 500's earnings would come from the oil industry and the continued drop in oil prices may be wiping out the chances of earnings increasing from the prior quarter. The earnings season unofficially kicks off tonight when Alcoa (AA) reports its fourth quarter earnings. ECONOMIC EVENTS: In the U.S., no major economic data was released. WTI and Brent crude both suffered slides of 5% during the session, sending WTI oil below $46 and Brent near $47 per barrel. Of note, Goldman Sachs said it sees oil prices bottoming in Q2 of this year at $42 a barrel. Goldman lowered its Brent crude oil price estimate for 2015 to $50 a barrel from $84 and for 2016 onwards to $70 a barrel from $90. COMPANY NEWS: Shire (SHPG) shares trading in New York slipped $8.39, or 3.86%, to $209.10 after the company announced over this weekend that it struck a deal to acquire NPS Pharmaceuticals (NPSP) for $46 per share in cash, for a total consideration of approximately $5.2B. NPS shares gained $3.44, or 8.21%, to $45.35... Shares of flash storage provider SanDisk (SNDK) dropped $13.47, or 13.88%, to $83.57 after the company cut its revenue outlook for Q4 and added that non-GAAP gross margin for the quarter is expected to be approximately 45%, compared to the previously guided range of 47%-49%. "The lower revenue was primarily due to weaker than expected sales of retail and iNAND products," SanDisk explained. Micron (MU) fell $1.87, or 5.56%, to $31.66 following the warning from its peer. MAJOR MOVERS: Among the notable gainers was Foundation Medicine (FMI), whose shares surged $22.81, or 95.32%, to $46.74 after the company and Roche (RHHBY) announced that they will enter into a strategic collaboration. Roche will invest in Foundation as part of the deal, resulting in Roche owning a minimum of 52.4% and a maximum of 56.3% of Foundation Medicine on a fully diluted basis. Also higher was Build-A-Bear Workshop (BBW), which jumped $3.12, or 16.75%, to $21.75 after the toy company gave a fourth quarter revenue view that beat expectations. Among the noteworthy losers was Arrowhead Research (ARWR), which fell $2.16, or 23.84%, to $6.90 after announcing that the FDA verbally informed the company of a partial clinical hold on its study of ARC-520 in patients with chronic hepatitis B infection. Also lower were shares of Sarepta Therapeutics (SRPT), which dropped $2.04, or 14.62%, to $11.91 after the company provided data through Week 168 from its Phase IIb open-label extension study of eteplirsen in patients with Duchenne muscular dystrophy. INDEXES: The Dow fell 96.53, or 0.54%, to 17,640.84, the Nasdaq lost 39.36, or 0.84%, to 4,664.71, and the S&P 500 declined 16.55, or 0.81%, to 2,028.26.
13:14 EDTGOOGAnalysts take opposite sides in regards to Google shares
Subscribe for More Information
12:46 EDTMUOn The Fly: Midday Wrap
Subscribe for More Information
11:19 EDTGOOGGoogle set to provide real-time translation via Translate app, NY Times reports
Subscribe for More Information
10:15 EDTMUOptions with decreasing implied volatility
Options with decreasing implied volatility: NBIX APOL NPSP BBBY INFY JCP MU TIF
10:00 EDTGOOGOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:40 EDTGOOGGoogle no longer fixing older Android security flaws, WSJ reports
Subscribe for More Information
09:34 EDTMUActive equity options trading
Subscribe for More Information
09:22 EDTGOOG23andMe announces collaboration with Pfizer
Google (GOOG)-backed 23andMe announced an agreement with Pfizer (PFE) that will provide Pfizer with access to 23andMe’s research platform, including services and Research Portal analysis of 23andMe’s genotyped population of over 800,000 individuals, of which more than 80 percent have consented to participate in research. 23andMe’s Research Portal enables qualified and approved scientists outside of 23andMe the opportunity to leverage the company’s unique research model while still protecting the privacy and security of 23andMe’s customers. As a part of the agreement, the companies will collaborate on certain genome-wide association studies, surveys, and clinical trial recruitment. One of these collaborations will be a longitudinal study to better understand the genetics of lupus. This study will entail enrollment and genotyping of 5,000 people into a new lupus research community, and include the integration of medical records, targeted bio-sampling along with genetic information for all participants. This announcement follows a collaboration between 23andMe and Pfizer to enroll 10,000 people with Inflammatory Bowel Disease in a research initiative designed to explore the genetic factors associated with the onset, progression, severity and response to treatments for IBD. Nearly 4,000 patients have been enrolled in the community since August 2014.
09:07 EDTMEETMeetMe sees FY15 revenue $47M-$53M, consensus $52.96M
MeetMe has updated its iPad app. The new iPad app streamlines the mobile experience across devices and includes simpler navigation and real time chat. The updated app for iPad also has a similar appearance to MeetMe’s iPhone and Android apps. “This update unifies the MeetMe experience across more mobile devices and makes future changes easier,” said Geoff Cook, CEO of MeetMe. “We look to continue improving our mobile experience across a range of devices to provide the best possible experience for our users. With this update, we are also laying the foundation for monetization of our iPad app in the coming weeks, when we plan to launch advertising and virtual currency on iPad. These expected revenues are included in our previously announced 2015 guidance of annual revenue growth to between $47M-$53M and annual adjusted EBITDA growth to between $7M-$10M.
09:03 EDTMUSanDisk drops 9% after cutting Q4 revenue outlook
Shares of flash storage provider SanDisk (SNDK) are sinking after the company cut its revenue outlook for Q4 to $1.73B from $1.80B-$1.85B. It added that non-GAAP gross margin for the quarter is expected to be approximately 45% compared to the previously guided range of 47%-49%. "The lower revenue was primarily due to weaker than expected sales of retail and iNAND products," SanDisk explained. The stock is dropping 9%, or $8.40, to $88.64 in pre-market trading while peer Micron (MU) is down 3% to $32.54.
08:21 EDTGOOGApple poised to gain market share, says JMP Securities
Subscribe for More Information
08:02 EDTGOOGGoogle shares undervalued, says Bernstein
Subscribe for More Information
07:38 EDTGOOGGoogle downgraded to Neutral from Overweight at Atlantic Equities
Subscribe for More Information
06:46 EDTGOOGGoogle downgraded to Neutral from Overweight at Atlantic Equities
Subscribe for More Information
January 11, 2015
21:04 EDTVRTXVertex expects Q4 Kalydeco revenue $460M
Subscribe for More Information
21:03 EDTVRTXVertex sees 2015 Kalydeco revenue $560M-$580M
Vertex expects that its combined non-GAAP R&D and SG&A expenses in 2015 will be in the range of $1.05B-$1.1B. It said the increase as compared to 2014 is primarily a result of launch preparation activities for lumacaftor in combination with ivacaftor and the planned pivotal Phase 3 development program for VX-661 in combination with ivacaftor. Vertex's expected non-GAAP R&D and SG&A expenses exclude stock-based compensation expense and certain other expenses recorded in 2015. Vertex said entered 2015 with approximately $1.4B in cash, cash equivalents and marketable securities. Anticipated 2015 Kalydeco net revenues reflect: Use of KALYDECO by eligible patients in Australia following the completion of reimbursement discussions in late 2014; Use of KALYDECO in people in the United States with the R117H mutation following FDA approval in late 2014; The completion of reimbursement discussions for gating mutations in certain European countries; Use of KALYDECO in children with CF ages 2 to 5 with the G551D or other gating mutations in the United States, based on potential approval in March 2015.
21:00 EDTVRTXVertex says NDA for combination of lumacaftor, ivacaftor accepted by FDA
Subscribe for More Information
20:57 EDTVRTXVertex says NDA for ivacaftor use in children accepted by FDA
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use